A5033578335- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
- Semantic Web and Ontologies
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Medical Imaging Techniques and Applications
- Biomedical Text Mining and Ontologies
- Scientific Computing and Data Management
- Ovarian cancer diagnosis and treatment
- DNA Repair Mechanisms
- Cancer Immunotherapy and Biomarkers
- Research Data Management Practices
- Neuroblastoma Research and Treatments
- Cancer Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Multiple Myeloma Research and Treatments
- Cancer Cells and Metastasis
AbbVie (United States)
2016-2025
University of Washington
2022
Memorial Sloan Kettering Cancer Center
2022
The Ohio State University
2022
University of Chicago
2022
Mayo Clinic in Florida
2022
Winthrop Rockefeller Foundation
2022
University of Oklahoma Health Sciences Center
2022
Women's Cancer Center of Nevada
2022
Jefferson Hospital
2022
Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance initial treatment patients high-grade serous ovarian carcinoma. In an international, phase 3, placebo-controlled trial, we assessed efficacy veliparib added to first-line induction carboplatin and paclitaxel continued monotherapy previously untreated stage III or IV Patients were randomly assigned a 1:1:1 ratio...
MEG3 is a maternally expressed imprinted gene suggested to function as non-coding RNA. Our previous studies suggest that has of tumor suppression. The suppressor p53 plays central role in suppression and mediates the functions many other suppressors. Therefore, we hypothesized through activation p53. We found transfection expression constructs for its isoforms results significant increase protein levels dramatically stimulates p53-dependent transcription from p53-responsive promoter. Using...
Abstract Background Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised a monoclonal antibody that binds activated EGFR (overexpressed wild-type EGFRvIII-mutant) linked to microtubule-inhibitor toxin in EGFR-amp GBMs. Methods In this phase III trial, adults with centrally confirmed,...
Telisotuzumab vedotin (Teliso-V) is a c-Met-directed antibody-drug conjugate with monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536) aimed to identify the optimal c-Met protein-overexpressing non-small cell lung cancer (NSCLC) population for treatment Teliso-V (stage I) and expand selected group efficacy evaluation II). Stage enrolled patients nonsquamous epidermal growth factor receptor (
There is no tumor-directed medical therapy available for Cushing's disease.The objective was to determine the in vitro effect of somatostatin analog pasireotide (SOM230) on cell proliferation human corticotroph tumors.Expression receptors (SSTR 1-5) determined by quantitative RT-PCR 13 tumors and immunohistochemistry (IHC) 12 tumors. SOM230 effects ACTH release were evaluated using primary cultures six adenomas.In our series, we found expression SSTR subtypes 1, 2, 4, 5 RT-PCR. All receptor...
Making data available as Linked Data using Resource Description Framework (RDF) promotes integration with other web resources. RDF documents can natively link to related data, and others back Uniform Identifiers (URIs). makes the machine-readable uses extensible vocabularies for additional information, making it easier scale up inference analysis.This paper describes recent developments in an ongoing project converting from ChEMBL database into triples. Relative earlier versions, this...
Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, an antibody-drug conjugate that preferentially binds cells EGFR amplification, internalized and releases potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, efficacy depatux-m monotherapy at recommended Phase 2 dose...
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II (RPTD), safety, and pharmacokinetics ABT-414 plus radiation temozolomide in newly diagnosed glioblastoma. is a first-in-class, tumor-specific antibody-drug conjugate that preferentially targets tumors expressing overactive epidermal growth factor receptor (EGFR).
Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse no clear standard of care for recurrent disease (rGBM). Approximately 50% patients tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody-drug conjugate depatuxizumab mafodotin (depatux-m) binds cells EGFR amplification, is internalized, and releases microtubule toxin, killing the cell. Here we report efficacy, safety pharmacokinetics (PK) depatux-m + temozolomide (TMZ) in...
The efficacy and safety of linifanib (ABT-869), a selective inhibitor vascular endothelial growth factor platelet-derived receptor tyrosine kinases, were assessed in this phase 2, single-arm, open-label, multicenter trial.Eligible patients had unresectable or metastatic hepatocellular carcinoma received ≤ 1 prior systemic therapy. Patients oral at fasting dose 0.25 mg/kg,. primary endpoint was the progression-free rate 16 weeks. Tumor response every 8 Secondary endpoints included time to...
Purpose: PARP plays an important role in DNA repair. Veliparib, a inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin paclitaxel. The primary endpoint this phase II trial determined whether addition veliparib to paclitaxel improved progression-free survival (PFS) previously untreated patients advanced/metastatic non-small cell lung cancer.Experimental Design: Patients were randomized 2:1 either or placebo. Veliparib (120 mg) placebo was given...
We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation temozolomide in newly diagnosed glioblastoma (arm A). The purpose this study was to evaluate the pharmacokinetics depatux-m, either combination with or recurrent B) as monotherapy C).In multicenter phase I dose escalation study, patients received depatux-m (0.5-1.5 mg/kg arm B, 1.25 C) every 2 weeks by intravenous infusion. Maximum tolerated...
Adding carboplatin to standard neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) likely benefits a subset of patients; however, determinants benefit are poorly understood.To define the association molecular subtype, tumor proliferation, and immunophenotype with added NAC for patients stages II III TNBC.This was prespecified secondary analysis phase 3, double-blind, randomized clinical trial (BrighTNess) that enrolled 634 women across 145 centers 15 countries. Women TNBC...
BACKGROUND Epidermal growth factor receptor ( EGFR ) alterations are associated with multiple cancers. Current EGFR‐directed therapies have led to increased efficacy but specific side effects. The antibody‐drug conjugate depatuxizumab mafodotin (depatux‐m) targets a monoclonal antibody linked cytotoxin, and is highly tumor‐specific. METHODS This phase 1/2 study evaluated the safety, pharmacokinetics, of depatux‐m in patients who had advanced solid tumors known wild‐type overexpression,...
c-Met is the receptor tyrosine kinase for hepatocyte growth factor (HGF) encoded by MET proto-oncogene. Aberrant activation of resulting from amplification and overexpression associated with poor clinical outcome in multiple malignancies underscoring importance signaling cancer progression. Several inhibitors have advanced to clinic; however, development inhibitory c-Met-directed therapeutic antibodies has been hampered inherent agonistic activity. We generated tested a bivalent anti-c-Met...
BackgroundThis open-label Phase III trial (NCT02264990) evaluated the PARP inhibitor, veliparib, combined with carboplatin/paclitaxel versus chemotherapy alone for first-line treatment of patients advanced non–squamous non–small cell lung cancers (NSCLC). A 52-gene expression classifier (LP52) previously shown to identify more likely respond veliparib was as a planned correlative analysis.Materials and MethodsAdult current or former smokers NSCLC were randomized 1:1 (120 mg daily 7...
Purpose ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I randomized double-blind II study of pemetrexed or placebo in patients recurrent advanced metastatic non–small-cell lung cancer (NSCLC). Methods One hundred seventy-one received intravenous 500 mg/m 2 day 1 oral days to 14 21-day cycles. The primary end point was progression-free survival (PFS). Secondary included overall (OS); pharmacokinetic pharmacodynamic...
ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of <sup>111</sup>In-radiolabeled (ABT-806i) effects repeated doses on occupancy. <b>Methods:</b> Eligible patients had advanced tumors likely to express EGFR/EGFRvIII; adequate performance status organ function; measurable disease by RECIST 1.1. In cohort 1, 6 received bolus administration ABT-806i underwent SPECT followed whole-body...
In VELIA trial, veliparib combined with carboplatin-paclitaxel, followed by maintenance (veliparib-throughout) was associated improved progression-free survival (PFS) compared carboplatin-paclitaxel alone in patients high-grade ovarian carcinomas. We explored the prognostic value of modeled cancer antigen (CA)-125 elimination rate constant K (KELIM), which is known to be an indicator intrinsic tumor chemosensitivity (the faster CA-125 decline, higher KELIM and chemosensitivity), its...